Gefitinib-sensitizing mutations in esophageal carcinoma.
Guo
Mingzhou
M
Liu
Shuang
S
Lu
Fengmin
F
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D004273:DNA, Neoplasm / Q000032:analysis; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D004935:Esophageal Diseases / Q000235:genetics / Q000473:pathology; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics*; D000077156:Gefitinib; D006801:Humans; D009154:Mutation; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D012333:RNA, Messenger; D066246:ErbB Receptors; D000077156:Gefitinib